Myositis disease
MONDO:0021167An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
Also known as: inflammation of muscle tissue, inflammatory disorder of muscle (disorder), muscle tissue inflammation
299 clinical trials for this condition and its sub-types, 105 tagged with Myositis disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myositis disease
-
Idiopathic inflammatory myopathy 61 trials · 181 incl. sub-types
2 sub-types
- Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types Sub-types →
- Familial idiopathic inflammatory myopathy 0 trials
-
Tendinitis 24 trials · 77 incl. sub-types
6 sub-types
- Patellar tendinitis 22 trials
- Tenosynovitis 4 trials · 14 incl. sub-types Sub-types →
- Calcific tendinitis 10 trials
- Achilles bursitis 7 trials
- Tibialis tendinitis 1 trial
- Paratenonitis 0 trials Sub-types →
-
Inclusion body myositis 35 trials · 38 incl. sub-types
2 sub-types
- GNE myopathy 3 trials
- Myopathy, proximal, and ophthalmoplegia 0 trials Sub-types →
-
Myositis ossificans 11 trials
1 sub-type
- Traumatic myositis ossificans 0 trials
-
Myositis fibrosa 1 trial
-
Bacterial myositis 0 trials
1 sub-type
- Pyomyositis 0 trials
-
Fungal myositis 0 trials
-
Idiopathic granulomatous myositis 0 trials
-
Infectious myositis 0 trials
1 sub-type
- Parasitic myositis 0 trials Sub-types →
-
Orbital myositis 0 trials
-
Viral myositis 0 trials
Most studied deeper sub-types
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control Stopped earlyThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC